Together, these results provide evidence of a dual role for PARP9 in regulating the type I IFN pathway and thereby influencing TB susceptibility, thus calling for caution when considering ARTDs such as PARP9 as new therapeutic targets to improve host TB immunity. This evidence concerns the gene PARP9 and tuberculosis.